Rocket Pharmaceuticals, Inc. (RCKT) News
Filter RCKT News Items
RCKT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RCKT News Highlights
- RCKT's 30 day story count now stands at 2.
- Over the past 3 days, the trend for RCKT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- RARE are the most mentioned tickers in articles about RCKT.
Latest RCKT News From Around the Web
Below are the latest news stories about ROCKET PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RCKT as an investment opportunity.
11 Most Promising Biotech Stocks to Buy According to AnalystsIn this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Most Promising Biotech Stocks to Buy According to Analysts. The biotech industry is making a resurgence […] |
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of DirectorsCRANBURY, N.J., December 12, 2023--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of R. Keith Woods as an independent, non-executive director to its Board of Directors. Mr. Woods is a seasoned executive with more than 30 years of experience spanning commercialization, global operations, business strategy and supply |
Billionaire Lee Ainslie’s Top 10 Stock PicksIn this article, we will take a look at Billionaire Lee Ainslie’s top 10 stock picks. For more Ainslie’s stocks, head on over to Billionaire Lee Ainslie’s Top 5 Stock Picks. Hedge fund managers are known for investing in various asset classes in the race to unlock value in the market. But not Lee Ainslie, a […] |
Rocket (RCKT) Surges 40% in 3 Months on Regulatory UpdatesRocket (RCKT) gains 40% in three months on positive regulatory updates on its key candidates. |
Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?The consensus price target hints at a 167.1% upside potential for Rocket Pharmaceuticals (RCKT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent ProgressCRANBURY, N.J., November 06, 2023--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial results for the quarter ending September 30, 2023, and updates from the Company’s key pipeline developments, business operations and upcoming milestones. |
With This Rally, Rocket Just Might Take OffLet me tell you why I and how I added this biotech name, and look at the bigger picture of the market and economy. Despite good news on a myriad of fronts, the stock was clearly swimming upstream as the biotech sector sold off hard over the past few months. This gene therapy developer garnered a priority review from the Food and Drug Administration early in October for its marketing application for potentially its first approved product, a candidate to treat Leukocyte Adhesion Deficiency-I, a rare immune disorder in children. |
Rocket Pharmaceuticals Stock Sees Improved Price StrengthRocket Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating |
Rocket Pharmaceuticals Stock Sees RS Rating Pops HigherA Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue? |
Should You Hold Rocket Pharmaceuticals (RCKT)?Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. The fund declined 6.05% (Institutional Shares) in the quarter compared to a 3.88% loss for the Russell 3000 Health Care Index and a 3.27% loss for the S&P 500 Index. […] |